美国众议院通过了《生物安保法》,将WuXi Apptec和Biologics称为“生物技术问题”,限制政府的合同,并要求参议院批准。 U.S. House passes Biosecure Act, labels WuXi AppTec and Biologics as "biotech concerns," restricting gov't contracts and requiring Senate approval.
美国众议院通过了《生物安保法》,将中国的生物技术公司WuXi AppTec和WuXi生物logics称为“受关注的生物技术公司”。 The U.S. House of Representatives has passed the Biosecure Act, labeling China-based biotech firms WuXi AppTec and WuXi Biologics as "biotechnology companies of concern." 该法案旨在限制美国政府与这些公司签订的合同,并援引两家公司都否认的国家安全风险。 The bill aims to restrict U.S. government contracts involving these companies, citing national security risks, which both firms deny. 宣布之后,它们的股票价格下跌。 Following the announcement, their stock prices fell. 这项立法仍需要参议院批准,并试图限制美国对中国生物技术的依赖。 The legislation still requires Senate approval and seeks to limit American reliance on Chinese biotech.